Number of patients | 57 (100%) | |
Gender, n | female | 56 (98%) |
male | 1 (2%) | |
Age, years | 60.0 (28-84) | |
Height, m | 1.56 (1.45-1.70) | |
Body weight, kg | 53.9 (40.3-100) | |
BMI, kg/m2 | 21.8 (17.2-40.2) | |
Histories, n | allergy | 26 (46%) |
smoking | 19 (33%) | |
alcohol consumption | 24 (42%) | |
Treatment settings, n | pre-operative | 20 (35%) |
post-operative | 10 (18%) | |
recurrent | 15 (26%) | |
stage IV | 12 (21%) | |
Drugs combined with Pmab-Tmab, n | docetaxel | 39 (68%) |
paclitaxel | 5 (9%) | |
capecitabine | 1 (2%) | |
exemestane | 1 (2%) | |
none | 11 (19%) | |
Previous history of chemotherapy, n | ||
any time | 45 (79%) | |
within 3 months | Total | 38 (67%) |
anthracycline + cyclophosphamide | 30 (53%) | |
paclitaxel | 1 (2%) | |
Tmab | 4 (7%) | |
Tmab + paclitaxel | 1 (2%) | |
lapatinib + capecitabine | 1 (2%) | |
capecitabine | 1 (2%) | |
none | 12 (21%) | |
Estrogen receptor, n | positive | 36 (63%) |
negative | 21 (37%) | |
IR occurrence, n | yes | 25 (44%) |
no | 32 (56%) |
Without IR (n = 32) |
With IR (n = 25) |
P-value | |
---|---|---|---|
Patient characteristics | |||
Age, years | 52 (28-84) | 64 (33-83) | 0.16 |
Height, m | 1.56 (1.45-1.68) | 1.56 (1.46-1.70) | 0.91 |
Body weight, kg | 55 (41-97) | 50 (40-100) | 0.092 |
BMI, kg/m2 | 22.4 (17-37) | 20.3 (17-40) | 0.058 |
History of allergy, n | 16 (50%) | 10 (40%) | 0.59 |
History of smoking, n | 8 (25%) | 11 (44%) | 0.30 |
History of alcohol consumption, n | 15 (47%) | 9 (36%) | 0.43 |
Estrogen receptor, n | |||
positive | 20 (63%) | 16 (64%) | 1.0 |
negative | 12 (38%) | 9 (36%) | |
Treatment settings, n | |||
pre-operative | 11 (34%) | 9 (36%) | 0.031* |
post-operative | 2 (6%) | 8 (32%) | |
recurrent | 12 (38%) | 3 (12%) | |
stage IV | 7 (22%) | 5 (20%) | |
Anti-cancer drug administration within 3 months before Pmab, n | |||
anthracycine | 13 (41%) | 17 (68%) | 0.061 |
none or other than anthracycline | 19 (59%) | 8 (32%) | |
Blood test data | |||
WBC, /μL | 5200 (2600-15300) | 5000 (1700-15700) | 0.57 |
NTR, /μL | 3400 (1600-12900) | 3500 (850-13500) | 0.63 |
LYM, /μL | 870 (370-2290) | 860 (200-2340) | 0.48 |
MON, /μL | 300 (160-980) | 320 (100-1600) | 0.76 |
RBC, 104/μL | 400 (300-500) | 350 (210-480) | <0.001 |
Hb, g/dL | 12.0 (9.6-14) | 10.8 (6.5-14) | 0.0011 |
Hct, % | 36 (30-44) | 32 (19-42) | <0.001 |
MCV, fL | 93 (81-100) | 93 (79-99) | 0.61 |
MCH, pg | 31 (24-42) | 31 (26-35) | 0.49 |
MCHC, % | 33 (30-35) | 34 (32-35) | 0.21 |
PLT, 104/μL | 27 (9.5-52) | 26 (4.6-55) | 0.69 |
NLR | 3.9 (1.1-14) | 4.0 (1.3-26) | 0.86 |
MLR | 0.36 (0.14-1.3) | 0.49 (0.11-1.3) | 0.37 |
PLR | 300 (110-1110) | 300 (140-1000) | 0.88 |
AST, U/L | 21 (10-53) | 21 (11-420) | 0.74 |
ALT, U/L | 17 (5-77) | 16 (8-91) | 0.64 |
ALP, U/L | 230 (60-650) | 240 (95-2900) | 0.50 |
γ-GTP, U/L | 28 (18-150) | 22 (15-1400) | 0.17 |
LDH, U/L | 220 (160-380) | 210 (140-1400) | 1.0 |
TP, g/dL | 6.9 (6.3-7.5) | 6.8 (5.8-7.9) | 0.27 |
Alb, g/dL | 4.1 (2.9-4.7) | 3.9 (2.4-4.5) | 0.11 |
BUN, mg/dL | 12 (7.0-55) | 13 (6.1-21) | 0.55 |
Cre, mg/dL | 0.59 (0.40-1.80) | 0.56 (0.41-0.81) | 0.81 |
CRP, mg/dL | 0.090 (0-3.9) | 0.070 (0-5.2) | 0.52 |
Variables | Odds ratio | Log odds ratio | 95% CI |
---|---|---|---|
Hb (P) | 0.22 | −1.53 | [0.044, 0.58] |
Hb (P) - Hb (A) | 0.29 | −1.25 | [0.092, 0.61] |
Hb (P)/HB (A) | 3.5 × 10−8 | −17.2 | [5.0 × 10−15, 1.1 × 10−3] |